PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 05:58:00·⟳ 抓取 05:58:21 +21s·⚡ 决策 08-27 06:01:34 +3m13s·61.9 天前
Hagens Berman再次提醒Aardvark投资者参与证券集体诉讼，核心事实仍是此前ARD-101临床暂停与FDA全临床搁置
本条没有新增FDA决定、临床数据、和解金额、法院实质进展或公司经营披露；只是已公开集体诉讼的再次招募提醒，不构成新的可交易催化。
📄 原文PR Newswire All News Releases↗ 原文
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notif…
不做 Aardvark Therapeutics（AARD.US）
不做：本条只是律所对已公开集体诉讼的重复提醒，核心ARD-101临床暂停和FDA full clinical hold均为旧事实；没有新增强空催化，也没有解除clinical hold的做多催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
AARD的真正负面基本面事件是ARD-101因心脏安全观察导致Phase 3 HERO/OLE暂停，随后FDA在2026-05-14实施full clinical hold；本次2026-08-26稿件仅复述这些旧事实并提醒投资者lead plaintiff期限。公开来源还显示同一律所已于2026-08-17发布相同诉讼提醒，因此新鲜度与增量均不足，既不适合追空，也不能反手做多。
消息传播链
- 公司宣布因健康志愿者研究中高于目标治疗剂量出现可逆心脏观察，自愿暂停Phase 3 HERO和OLE试验。市场反应:本次PR稿称该消息后AARD股价下跌逾56%。
- 公司宣布FDA对ARD-101 IND实施full clinical hold，适用于HERO和OLE等所有相关进行中研究。市场反应:本次PR稿称该消息后AARD股价再跌32.1%。
- Hagens Berman已发布AARD集体诉讼投资者提醒，内容与本次PR Newswire稿件高度重合。
- 本次信号为律所再次提醒投资者lead plaintiff期限和诉讼指控，没有新增clinical hold、试验数据或法院实质进展。
关键理由
- 本次诉讼提醒不新增临床、监管或财务事实，交易上应视为旧负面事件的二次传播。
- FDA full clinical hold和HERO/OLE暂停已分别在2026-05-14和2026-02-27由公司披露，非本条新闻首次揭示。
- AARD近期股价已围绕旧临床搁置与诉讼信息波动，本条缺乏新增量级可支撑新的方向性交易。
主要风险
- 若后续出现法院受理重大进展、和解金额、SEC调查或FDA解除/延长clinical hold，需重新评估。
- 小市值临床阶段生物科技股波动很高，单纯诉讼提醒可能带来盘后情绪扰动但不等于可重复交易edge。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-11 · 影响 weakens
公司二季报称仍与FDA沟通、评估HERO/OLE已揭盲数据且现金为7390万美元；没有本次稿件新增的强空事实。
检索:Aardvark Therapeutics ARD-101 FDA clinical hold August 2026 update unblind HERO OLE cash 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-11 · 影响 none
未见FDA clinical hold已解除或ARD-101恢复原设计Phase 3试验的官方确认，不能反手做多。
检索:Aardvark Therapeutics FDA clinical hold resolved ARD-101 August 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；决定性因素是同一诉讼提醒已在2026-08-17出现，且核心临床/FDA事实已在数月前披露。
方向:律师事务所重复发布证券集体诉讼提醒通常更接近旧闻扩散，不能单独推出新增方向。
涨幅量级:未取得可用event_study样本，且本事件缺少新增基本面量级，不能据先例设定tp/sl。
形态:本次主要风险是旧利空重复传播后的见光无反应，而非新负面重估。
原文全文
展开原文 · 4,107 字
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.
Key Case Details & Important Deadlines
- Lead Plaintiff Motion Deadline: October 13, 2026
- Visit: www.hbsslaw.com/cases/aardvark-therapeutics-inc-aard-securities-class-action
What is the Lawsuit About?
The complaint alleges that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and/or failed to disclose critical information.
Specifically, the action points out that the offering documents and defendants failed to disclose:
- That ARD-101 was significantly less safe than defendants had led investors to believe;
- That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and
- Consequently, Aardvark's clinical, regulatory, and commercial prospects—including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)—were materially overstated.
The Truth Emerges: Voluntarily Pause and FDA Clinical Hold
- February 27, 2026: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study." Following this news, Aardvark's stock price plummeted over 56%.
- May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark's stock price fell another 32.1%.
Hagens Berman's Investigation
"We're investigating the suit's allegations, including that Aardvark allegedly misled investors about ARD-101's development, its safety and efficacy," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims in the pending suit.
What Can Aardvark Investors Do?
If you are a class member who suffered losses on Aardvark securities, you have until October 13, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.
If you'd like more information and answers to frequently asked questions about the firm's Aardvark investigation, read more »
Whistleblowers: Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.
Key Case Details & Important Deadlines
- Lead Plaintiff Motion Deadline: October 13, 2026
- Visit: www.hbsslaw.com/cases/aardvark-therapeutics-inc-aard-securities-class-action
What is the Lawsuit About?
The complaint alleges that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and/or failed to disclose critical information.
Specifically, the action points out that the offering documents and defendants failed to disclose:
- That ARD-101 was significantly less safe than defendants had led investors to believe;
- That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and
- Consequently, Aardvark's clinical, regulatory, and commercial prospects—including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)—were materially overstated.
The Truth Emerges: Voluntarily Pause and FDA Clinical Hold
- February 27, 2026: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study." Following this news, Aardvark's stock price plummeted over 56%.
- May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark's stock price fell another 32.1%.
Hagens Berman's Investigation
"We're investigating the suit's allegations, including that Aardvark allegedly misled investors about ARD-101's development, its safety and efficacy," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims in the pending suit.
What Can Aardvark Investors Do?
If you are a class member who suffered losses on Aardvark securities, you have until October 13, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.
If you'd like more information and answers to frequently asked questions about the firm's Aardvark investigation, read more »
Whistleblowers: Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。